Medtronic's Dividend Could Not Repair a Five-Year Return Gap

Medtronic's dividend helped shareholders, but it did not rescue their five-year result.

From October 20, 2021, to October 28, 2026, Medtronic's share price fell 22.2%, while the S&P 500 rose 70.7%, according to Trefis. Reinvested dividends improved Medtronic's return to negative 8.7%. The same treatment lifted the market return, measured through the SPDR S&P 500 ETF, to 82.1%.

The dividend therefore narrowed the total-return gap by only about two percentage points. It added 13.5 percentage points to Medtronic's result, but S&P 500 dividends added 11.4 points to the benchmark. Income investors received cash, yet the weak share price still dominated the outcome.

That history should not be confused with the current safety of the dividend. Medtronic generated $5.43 billion of free cash flow in fiscal 2026 and paid $3.64 billion of dividends. On those figures, free cash flow covered the dividend about 1.49 times. After $1.04 billion of share repurchases, free cash flow covered the two forms of shareholder return about 1.16 times. These BTI calculations use Medtronic's reported fiscal 2026 cash-flow figures and do not imply that future coverage will be identical.

The company also raised its quarterly dividend to $0.72 a share, equivalent to $2.88 annually, marking its 49th consecutive annual increase. The record is valuable, but the coverage ratio is more informative than the streak because it shows how much cash remains after the payout.

Operations entered fiscal 2027 with stronger growth. First-quarter revenue rose 13.7% to $9.76 billion, and management raised organic revenue growth guidance to 7.25% to 7.75%. It also raised the lower end of non-GAAP diluted earnings guidance, setting a range of $5.94 to $6.00. The quarter contained an extra fiscal week that management estimated added about $570 million to organic growth, so the headline rate overstates the underlying acceleration.

The portfolio has also changed. Medtronic completed the separation of MiniMed on October 15, exchanging its remaining 252.8 million MiniMed shares through an offer that was 5.4 times subscribed. The company now centers its strategic focus on cardiovascular, neuroscience and surgical businesses. Cardiovascular produced 38.4% of fiscal 2026 revenue, according to Trefis, making its growth and margins especially important to the dividend base.

MiniMed's exit removes a fast-growing diabetes business from future consolidated comparisons and can complicate year-over-year analysis. Investors should distinguish reported growth, organic growth and growth in the continuing portfolio rather than treating them as equivalent.

The five-year return record is a reminder that a dividend cannot compensate indefinitely for capital loss. The forward question is more constructive: can Medtronic convert its improving operating performance into free cash flow that grows faster than the dividend? Fiscal 2026 coverage says the payout was funded. Sustained revenue growth, cash conversion and discipline after the MiniMed separation will determine whether shareholders receive both income and capital appreciation.